

GARVAN INSTITUTE PUBLICATIONS 2001

- 1 Abad V, Chrousos GP, Reynolds JC, Nieman LK, Hill SC, Weinstein RS, Leong GM. Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. *J Bone Miner Res* 2001; 16:1879-1885.
- 2 Arthur JF, Matkovich SJ, Mitchell CJ, Biden TJ, Woodcock EA. Evidence for selective coupling of α_1 -adrenergic receptors to phospholipase C- β_1 in rat neonatal cardiomyocytes. *J Biol Chem* 2001; 276:37341-37346.
- 3 Badenhop RF, Cherian S, Lord RSA, Baysal BE, Taschner PEM, Schofield PR. Novel mutations in the *SDHD* gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. *Gene Chromosome Canc* 2001; 31:255-263.
- 4 Badenhop RF, Moses MJ, Scimone A, Mitchell PB, Ewen KR, Rosso A, Donald JA, Adams LJ, Schofield PR. A genome screen of a large bipolar affective disorder pedigree supports prior evidence for a susceptibility locus on chromosome 13q. *Mol Psychiatr* 2001; 6:396-403.
- 5 Bell NH, Morrison NA, Nguyen TV, Eisman JA, Hollis BW. *APAI* polymorphisms of the vitamin D receptor predict bone density of the lumbar spine and not racial difference in bone density in young men. *J Lab Clin Med* 2001; 137:133-140.
- 6 Biankin AV, Kench JG, Morey AL, Lee C-S, Biankin SA, Head D, B HT, Henshall SM, Sutherland RL. Overexpression of p21^{WAF1/CIP1} is an early event in the development of pancreatic intraepithelial neoplasia. *Cancer Res* 2001; 61:8830-8837.
- 7 Brown MA, Houghton MA, Grant SFA, Gunnell AS, Henderson NK, Eisman JA. Genetic control of bone density and turnover: role of the collagen 1 α 1, estrogen receptor, and vitamin D receptor genes. *J Bone Miner Res* 2001; 16:758-764.
- 8 Burgess AJ, Pavey S, Hunter L-J, Piva TJ, Fairlie DP, Musgrove EA, Saunders N, Parsons PG, Gabrielli BG. Up-regulation of p21^{WAF1/CIP1} by histone deacetylase inhibitors reduces the efficacy of these drugs. *Mol Pharmacol* 2001; 60:828-837.
- 9 Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase C ζ activation mediates glucagon-like peptide-1-induced pancreatic β -cell proliferation. *Diabetes* 2001; 50:2237-2243.
- 10 Campbell L, Rössner S. Management of obesity in patients with Type 2 diabetes. *Diabetic Med* 2001; 18:345-354.
- 11 Carpenter L, Cordery D, Biden TJ. Protein kinase C δ activation by interleukin-1 β stabilizes inducible nitric-oxide synthase mRNA in pancreatic β -cells. *J Biol Chem* 2001; 276:5368-5374.
- 12 Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with lactic acidemia and weight pre-antiretroviral therapy. *AIDS* 2001; 15:703-709.
- 13 Carroll JS, Prall OWJ, Sergio CM, Rogan EM, Watts CKW, Musgrove EA, Sutherland RL. Estrogen/estrogen antagonist regulation of the cell cycle in breast cancer cells. In: Burnstein KL, editor. *Steroid hormones and cell cycle regulation*. Boston: Kluwer Academic Publishers; 2001. p. 57-71.
- 14 Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C. A role for protein phosphatase 2A-like activity, but not atypical protein kinase C ζ , in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. *Diabetes* 2001; 50:2210-2218.
- 15 Chai Z, Sarcevic B, Mawson A, Toh B-H. SET-related CDA1 (cell division autoantigen-1) arrests cell growth. *J Biol Chem* 2001; 276:33665-33674.
- 16 Chtanova T, Kemp RA, Sutherland APR, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4 and CD8 type 1 and type 2 T cells. *J Immunol* 2001; 167:3057-3063.
- 17 Chtanova T, Mackay CR. T cell effector subsets: extending the Th1/Th2 paradigm. *Adv Immunol* 2001; 78:233-266.
- 18 Church WB, Inglis AS, Tseng A, Duell R, Lei P-W, Bryant KJ, Scott KF. A novel approach to the design of inhibitors of human secreted phospholipase A₂ based on native peptide inhibition. *J Biol Chem* 2001; 276:33156-33164.

- 19 Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallupp M, Schofield P, Masters CL, Currie J. Memory decline in healthy older people: implications for identifying mild cognitive impairment. *Neurology* 2001; 56:1533-1538.
- 20 Corthals GL, Gygi SP, Aebersold R, Patterson SD. Identification of proteins by mass spectrometry. In: Rabilloud T, editor. *Proteome research: two-dimensional gel electrophoresis and detection methods*. Heidelberg: Springer Verlag; 2001. p. 197-231.
- 21 Corthals GL, Nelson PS. Large-scale proteomics and its future impact on medicine. *Pharmacogenomics* 2001; 1:15-19.
- 22 Cox HM, Pollock EL, Tough IR, Herzog H. Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. *Peptides* 2001; 22:445-452.
- 23 Craven AJ, Ormandy CJ, Robertson FG, Wilkins RJ, Kelly PA, Nixon AJ, Pearson AJ. Prolactin signaling influences the timing mechanism of the hair follicle: analysis of hair growth cycles in prolactin receptor knockout mice. *Endocrinology* 2001; 142:2533-2539.
- 24 Dastmalchi S, Morris MB, Church WB. Modelling of the structural features of integral-membrane proteins using REPIMPS (reverse-environment prediction of integral membrane protein structure). *Protein Sci* 2001; 10:1529-1538.
- 25 Dow R, Hendley J, Pirkmaier A, Musgrove E, Germain D. Retinoic acid-mediated growth arrest requires ubiquitlyation and degradation of the F-box protein Skp2. *J Biol Chem* 2001; 276:45945-45951.
- 26 Doyle KL, Khan M, Cunningham AM. Expression of the intermediate filament protein, nestin, by sustentacular cells in mature olfactory neuroepithelium. *J Comp Neurol* 2001; 437:186-195.
- 27 Eisman JA. Pharmacogenetics of the vitamin D receptor and osteoporosis. In: *Drug Metab Dispos*; 2001; 2001. p. 505-512.
- 28 Eisman JA. Options for osteoporosis treatment in the elderly (commentary). *BoneKey-Osteovision (electronic journal)* 2001; 1:2001040.
- 29 Elder GJ. Pathogenesis and management of hyperparathyroidism in end stage renal disease and after renal transplantation. *Nephrology* 2001; 6:155-160.
- 30 Furler SM, Poynten AM, Kriketos AD, Lowy AJ, Ellis BA, Maclean EL, Courtenay BG, Kraegen EW, Campbell LV, Chisholm DJ. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. *Obes Res* 2001; 9:535-543.
- 31 Gan SK, Chisholm DJ. The glucose tolerance test. In: Dunstan R, editor. *Abnormal Lab Results*. Roseville, Australia: McGraw-Hill; 2001. p. 56-62.
- 32 Gan SK, Chisholm DJ. The type 2 diabetes epidemic: a hidden menace. *Med J Australia* 2001; 175:65-66.
- 33 Gan SK, Samaras K, Carr A, Chisholm D. Anti-retroviral therapy, insulin resistance and lipodystrophy. *Diabetes Obes Metab* 2001; 3:67-71.
- 34 Goumain M, Voisin T, Lorinet A-M, Ducroc R, Tsocas A, Roze C, Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y₂ receptor: pharmacological evidence and molecular cloning. *Mol Pharmacol* 2001; 60:124-134.
- 35 Graham GG, Robins S-A, Bryant KJ, Scott KF. Inhibition of prostaglandin synthesis in intact cells by paracetamol (actaminophen). *Inflammopharmacology* 2001; 9:131-142.
- 36 Greenfield JR, Center JR, Freund J, Eisman JA. Treatment of an atraumatic fracture: importance of establishing a definitive diagnosis. *J Bone Miner Res* 2001; 16:2362.
- 37 Greenfield JR, Chisholm DJ. Adrenal apoplexy: an inconspicuous cause of hypotension in the intensive care patient. *Med J Australia* 2001; 175:384-385.
- 38 Harris M, Hauser S, Nguyen TV, Walker JL, Rooddon C, Morton J, Freezer N, Strauss BJG, Kelly PJ, Eisman JA. Bone mineral density in prepubertal asthmatics receiving inhaled and intermittent oral corticosteroids. *J Paediatr Child Health* 2001; 37:67-71.
- 39 Hayward CS, Samaras K, Campbell L, Kelly RP. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. *Am J Hypertens* 2001; 14:699-703.
- 40 Henderson K, Eisman J, Keogh A, Macdonald P, Glanville A, Spratt P, Sambrook P. Protective effect of short term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. *J Bone Miner Res* 2001; 16:565-571.
- 41 Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Overexpression of the cell cycle inhibitor p16^{INK4A} in high grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. *Clin Cancer Res* 2001; 7:544-550.

- 42 Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. *Cancer Res* 2001; 61:423-427.
- 43 Herrera C, Casado V, Ciruela F, Schofield P, Mallol J, Lluís C, Franco R. Adenosine A_{2B} receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. *Mol Pharmacol* 2001; 59:127-134.
- 44 Ho KKY. Growth hormone deficiency in adults. In: DeGroot LJ, Jameson JL, editors. *De Groot's Textbook of Endocrinology*. 4th ed. Philadelphia: W B Saunders Company; 2001. p. 520-527.
- 45 Ho KKY, O'Sullivan A, Hoffman D, Leung K-C. Growth hormone action in man: physiology and pathology. In: Bouloin R, editor. *Targets for growth hormone and IGF-1 action*; 2001; Bristol: Bioscientifica; 2001. p. 1-11.
- 46 Horvath L, Henshall S. The application of tissue microarrays to cancer research. *Pathology* 2001; 33:125-129.
- 47 Horvath LG, Henshall SM, Lee C-S, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson J-A, Sutherland RL. Frequent loss of estrogen receptor- β expression in prostate cancer. *Cancer Res* 2001; 61:5331-5335.
- 48 Issa LL, Leong GM, Barry JB, Sutherland RL, Eisman JA. Glucocorticoid receptor-interacting protein-1 and receptor-associated coactivator-3 differentially interact with the vitamin D receptor (VDR) and regulate VDR-retinoid X receptor transcriptional cross-talk. *Endocrinology* 2001; 142:1606-1615.
- 49 Jacoby AS, Iismaa TP. Galanin receptors. *Trends Pharmacol Sci Receptor and Ion Channel Nomenclature* 2001; Suppl S:48-49.
- 50 Jankova L, Harrop SJ, Saunders DN, Andrews JL, Bertram KC, Gould AR, Baker MS, Curmi PMG. Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop. *J Biol Chem* 2001; 276:43374-43382.
- 51 Jones G, Chisholm D. Diabetes monitoring: use of glycated haemoglobin and glycated protein assays (revised). In: Dunstan R, editor. *Abnormal lab results*: McGraw-Hill; 2001. p. p63-68.
- 52 Kam GYW, Wolthers T, Ho KKY. Effects of growth hormone on sodium homeostasis. In: Giustina A, editor. *Growth hormone and the heart*. Norwell, Massachusetts: Kluwer Academic Publishers; 2001. p. pp.165-174.
- 53 Kraegen EW, Cooney GJ, Ye J, Thompson AL. Triglycerides, fatty acids and insulin resistance - hyperinsulinemia. In: *Exp Clin Endocrinol Diab*; 2001; 2001. p. S516-S526.
- 54 Kraegen EW, Cooney GJ, Ye J-M, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in Type II diabetes and obesity. *Exp Clin Endocrinol Diabetes* 2001; 109 (Suppl 2):S189-S201.
- 55 Kwok JBJ, Raskin S, Morgan G, Antoniuk SA, Bruk I, Schofield PR. Mutations in the glycine receptor α 1 subunit (GLRA1) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of Y279C mutation. *J Med Genet* 2001; 38:e17.
- 56 Lai A, Sarcevic B, Prall OWJ, Sutherland RL. Insulin/IGF-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21^{WAF1/Cip1}. *J Biol Chem* 2001; 276:25823-25833.
- 57 Leong GM, Center JR, Henderson NK, Eisman JA. Glucocorticoid-induced osteoporosis: basic pathological mechanisms, clinical features and management in the new millennium. In: Marcus R, Feldman D, Kelsey J, editors. *Osteoporosis*. 2nd ed. San Diego: Academic Press; 2001. p. 169-193.
- 58 Leong GM, Subramaniam N, Figueroa J, Flanagan J, Hayman MJ, Eisman JA, Kouzmenko AP. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor- β -dependent transcription. *J Biol Chem* 2001; 276:18243-18248.
- 59 Leung K-C, Ho KKY. Measurement of growth hormone, insulin-like growth factor I and their binding proteins: the clinical aspects. In: Elsevier, editor. *Clin Chim Acta*; 2001; 2001. p. 119-123.
- 60 Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamarias M, Zhang J-G, Starr R, Hilton DJ, Ormandy CO, Alexander WS, Visvader J. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor deficient mice. *Gene Dev* 2001; 15:1631-1636.
- 61 Lynch JW, Han N-IR, Haddrill J, Pierce KD, Schofield PR. The surface accessibility of the glycine receptor M2-M3 loop is increased in the channel open state. *J Neurosci* 2001; 21:2589-

- 2599.
- 62 Lyons RJ, Deane R, Lynch DK, Ye Z-S, Sanderson GM, Eyre HJ, Sutherland GR, Daly RJ. Identification of a novel human tankyrase through its interaction with the protein Grb14. *J Biol Chem* 2001; 276:17172-17180.
- 63 Mackay CR. The chemokines: immunology's high impact factors. *Nat Immunol* 2001; 2:95-101.
- 64 Mackay CR, von Andrian UH. Memory T cells - local heroes in the struggle for immunity. *Science* 2001; 291:2323-2324.
- 65 Malaney S, Daly RJ. The Ras signaling pathway in mammary tumorigenesis and metastasis. *J Mammary Gland Biol Neopl* 2001; 6:101-113.
- 66 Matassa AA, Carpenter L, Biden TJ, Humphries MJ, Reyland ME. PKC δ is required for mitochondrial-dependent apoptosis in salivary epithelial cells. *J Biol Chem* 2001; 276:29719-29728.
- 67 McClellan KA, Robertson FG, Kindblom J, Wennbo H, Tornell J, Bouchard B, Kelly PA, Ormandy CJ. Investigation of the role of prolactin in the development and function of the lacrimal and Harderian glands using genetically modified mice. *Invest Ophth Vis Sci* 2001; 42:23-30.
- 68 McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP. Elevated androgens and prolactin in aromatase deficient mice (*ArKO*) cause enlargement but not malignancy of the prostate gland. *Endocrinology* 2001; 142:2458-2467.
- 69 Melrose WD, Ramsay A, Duell R, Scott KF, Turner PF, Brown R. Serum secretory phospholipase A2 type IIA is increased after diethylcarbamazine treatment of lymphatic filariasis and may be implicated in the post-treatment reaction. *J Infect Dis* 2001.
- 70 Mitchell CJ, Kelly MM, Blewitt M, Wilson JR, Biden TJ. Phospholipase C- γ mediates the hydrolysis of phosphatidylinositol, but not of phosphatidylinositol 4,5-bisphosphate, in carbamylcholine-stimulated islets of langerhans. *J Biol Chem* 2001; 276:19072-19077.
- 71 Morgan B. A cure for cancer? *Australian Medicine* 2001; February:8.
- 72 Nahum A, Hirsch K, Danilenko M, Watts CKW, Prall OWJ, Levy J, Sharoni Y. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27^{Kip1} in the cyclin E-cdk2 complexes. *Oncogene* 2001; 20:3428-3436.
- 73 Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. Targeted inactivation of G_n/tissue transglutaminase II. *J Biol Chem* 2001; 276:20673-20678.
- 74 Nguyen TV, Center JR, Sambrook PN, Eisman JA. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women. *Am J Epidemiol* 2001; 153:587-595.
- 75 Ormandy CJ, Horseman ND, Naylor M, Harris J, Robertson F, Binart N, Kelly PA. Mammary gland development. In: Horseman ND, editor. *Prolactin*. Boston: Kluwer; 2001. p. pp219-232.
- 76 Pierce KD, Handford CA, Morris R, Vafa B, Dennis JA, Healy PJ, Schofield PR. A nonsense mutation in the $\alpha 1$ subunit of the inhibitory glycine receptor associated with bovine myoclonus. *Mol Cell Neurosci* 2001; 17:354-363.
- 77 Prall OWJ, Carroll JS, Sutherland RL. A low abundance pool of nascent p21^{WAF1/Cip1} is targeted by estrogen to activate cyclin E-Cdk2. *J Biol Chem* 2001; 276:45433-45442.
- 78 Qu W, Moorhouse AJ, Cunningham AM, Barry PH. Anomalous mole-fraction effects in recombinant and native cyclic nucleotide-gated channels in rat olfactory receptor neurons. *Proc R Soc Lond B* 2001; 268:1395-1403.
- 79 Quinn DI, Henshall SM, Haynes A-M, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD. Prognostic significance of pathologic features in localised prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. *J Clin Oncol* 2001; 19:3692-3705.
- 80 Rees MI, Lewis T, Vafa B, Ferrie C, Corry P, Muntoni F, Jungbluth H, Stephenson JBP, Kerr M, Snell R, Schofield P, Owen MJ. Compound heterozygosity and nonsense mutations in the $\alpha 1$ -subunit of the inhibitory glycine receptor in hyperkplexia. *Hum Genet* 2001; 109:267-270.
- 81 Ross RJM, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KKY. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegovisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. *J Clin Endocrinol Metab* 2001; 86:1716-1723.
- 82 Sainsbury A, Herzog H. Inhibitory effects of central neuropeptide Y on the somatotrophic and gonadotrophic axes in male rats are independent of adrenal hormones. *Peptides* 2001; 22:467-471.

- 83 Sainsbury A, Wilks D, Cooney GJ. Central but not peripheral glucocorticoid infusion in adrenalectomized male rats increases basal and substrate-induced insulinemia through a parasympathetic pathway. *Obes Res* 2001; 9:274-281.
- 84 Saunders DN, Jankova L, Harrop SJ, Curmi PMG, Gould AR, Ranson M, Baker MS. Interaction between the P14 residue and strand 2 of β -sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2. *J Biol Chem* 2001; 276:43383-43389.
- 85 Schneider P, Takatsuka H, Wilson A, Tardivel A, Mackay F, Lens S, Finke D, Beermann F, Tschopp J. Maturation of marginal zone and follicular B cells requires BAFF and is independent of BCMA. *J Exp Med* 2001; 194:1691-1697.
- 86 Schofield PR. Genetics, an alternate way to discover, characterise and understand ion channels. In: *Clin Exp Pharmacol Physiol*; 2001; 2001. p. 84-88.
- 87 Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, Robertson SA, Krilis SA. Impaired thrombin generation in β_2 -glycoprotein I null mice. *J Biol Chem* 2001; 276:13817-13821.
- 88 Smith MJ, Kwok JBJ, McLean CA, Kril JJ, Broe GA, Nicholson GA, Cappai R, Hallupp M, Cotton RGH, Masters CL, Schofield PR, Brooks WS. Variable phenotype of Alzheimer's disease with spastic paraparesis. *Ann Neurol* 2001; 49:125-129.
- 89 Stanford PM, Halliday GM, Brooks WS, Kwok JBJ, Schofield PR. Progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17 and familial tauopathies (Letter). *Brain* 2001; 124:1668-1670.
- 90 Subramaniam N, Leong GM, Cock T-A, Flanagan J, Fong C, Eisman JA, Kouzmenko AP. Cross-talk between 1,25-dihydroxyvitamin D₃ and transforming growth factor- β signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. *J Biol Chem* 2001; 276:15741-15746.
- 91 Sunn KL, Cock T-A, Crofts LA, Eisman JA, Gardiner EM. Novel N-terminal variant of human VDR. *Mol Endocrinol* 2001; 15:1599-1609.
- 92 Thomas GP, Baker SUK, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. *J Endocrinol* 2001; 170:451-460.
- 93 Wang Y, Xu A, Ye J, Kraegen EW, Tse CA, Cooper GJS. Alteration in phosphorylation of P20 is associated with insulin resistance. *Diabetes* 2001; 50:1821-1827.
- 94 Wilson JR, Ludowyke RI, Biden TJ. A redistribution of actin and myosin IIA accompanies Ca²⁺-dependent insulin secretion. *FEBS Lett* 2001; 492:101-106.
- 95 Ye J-M, Doyle PJ, Iglesias MA, Watson DG, Cooney GC, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)- α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR- γ activation. *Diabetes* 2001; 50:411-417.
- 96 Ye J-M, Lim-Fraser M, Cooney GJ, Cooper GJS, Iglesias MA, Watson DG, Choong B, Kraegen EW. Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. *Am J Physiol (Endocrinol Metab)* 2001; 280:E562-E569.
- 97 Eisman JA. Good, good, good ... good vibrations; a better option for better bones? (commentary). *Lancet* 2001*; 358:1924.
- 98 Ho KKY. Place of pegvisomant in acromegaly. *Lancet* 2001*; 358:1743.
- 99 Musgrove EA, Hunter L-JK, Lee CSL, Swarbrick A, Hui R, Sutherland RL. Cyclin D1 overexpression induces progesterin resistance in T-47D breast cancer cells despite p27^{Kip1} association with cyclin E-Cdk2. *J Biol Chem* 2001*; 276:47675-47683.
- 100 Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KKY. Oral oestrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. *Am J Physiol Endocrinol Metab* 2001*; 281:E1191-E1196.